Abaloparatide

Background

Abaloparatide is a synthetic 34‑amino‑acid analog of human parathyroid hormone–related peptide (PTHrP) designed as an osteoanabolic agent for osteoporosis.[11][14] It is identical to human PTHrP at positions 1–22, with multiple substitutions in residues 23–34 to increase stability and optimize signaling at the parathyroid hormone type 1 receptor (PTH1R).[1][11][14] The developmental code name was BA058, and the marketed US trade name is Tymlos.[9][12][14]

The drug was developed to exploit the bone‑forming (anabolic) actions of intermittent PTH/PTHrP receptor activation while minimizing the hypercalcemia and bone resorption seen with earlier agents such as teriparatide.[1][11][14] Preclinical work demonstrated that abaloparatide produces robust increases in bone formation markers and bone mass with relatively less stimulation of bone resorption compared with teriparatide.[1][11][13]

Abaloparatide received its first major regulatory approval from the US Food and Drug Administration (FDA) in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.[9][11][12] It represents the second osteoanabolic drug class member after teriparatide.[11][12] In Europe, a marketing authorization under the trade name Eladynos was granted but later withdrawn at the request of the marketing authorization holder before commercial launch; as of the most recent regulatory documents, abaloparatide is not widely marketed in the EU.[9]

Beyond osteoporosis, preclinical studies have explored its potential in bone regeneration, osteoarthritis‑related cartilage repair, and craniofacial or alveolar bone augmentation, but these remain investigational.[2][4][7]

Mechanism of action

Abaloparatide is a PTHrP(1‑34) analog that acts as a selective agonist at parathyroid hormone receptor type 1 (PTH1R), a class B G protein–coupled receptor expressed primarily in bone and kidney.[1][5][11] PTH1R exists in at least two conformational states, termed R^G (G protein–coupled, GTPγS‑sensitive) and R^0 (G protein–uncoupled).[1] PTH and PTHrP analogs differ in their relative binding and signaling kinetics at these states.

Abaloparatide was engineered to favor transient binding to the R^G state with relatively rapid dissociation, resulting in short‑lived cyclic AMP (cAMP) signaling compared with PTH(1‑34).[1][13] This transient cAMP signal preferentially stimulates osteoblastic bone formation while limiting the sustained osteoclastogenic stimulus (via receptor activator of nuclear factor κB ligand, RANKL) associated with chronic PTH1R activation.[1][11][13]

At the cellular level, intermittent abaloparatide exposure activates Gs–cAMP–protein kinase A (PKA) pathways in osteoblasts and osteoblast precursors, increasing expression of osteogenic genes, promoting osteoblast number and activity, and enhancing bone formation rate.[1][11][13] In rodent and primate models, this translates into increased trabecular and cortical bone mass, improved microarchitecture, and greater bone strength at vertebral and nonvertebral sites.[11][13]

Preclinical comparative studies demonstrate that abaloparatide exhibits greater cAMP stimulation and β‑arrestin recruitment than teriparatide at PTH1R, with a lower EC50 for these signaling outputs, while still maintaining a favorable bone formation to resorption profile.[13] The net effect is a pronounced osteoanabolic response with comparatively lower rates of hypercalcemia than teriparatide in clinical use.[9][11]

Evidence summary

Key phase 3 fracture trial (ACTIVE)

The pivotal ACTIVE trial (Abaloparatide Comparator Trial In Vertebral Endpoints) was a randomized, double‑blind, placebo‑ and active‑controlled phase 3 study in postmenopausal women with osteoporosis.[9][11][12][14] Approximately 2463 women were randomized to daily subcutaneous abaloparatide 80 µg, placebo, or open‑label teriparatide 20 µg for 18 months.[9][11][12]

Major outcomes:[9][11][12][14]

• New morphometric vertebral fractures: abaloparatide reduced incidence to 0.58% vs 4.22% with placebo over 18 months (relative risk reduction ~86%).
• Nonvertebral fractures: significant reduction with abaloparatide vs placebo; hazard ratios in the range of ~0.57–0.67 depending on the analysis.
• Bone mineral density (BMD): abaloparatide produced large BMD gains at lumbar spine (~11.2%), total hip (~4.2%), and femoral neck (~3.6%) at 18 months, generally greater than teriparatide at hip and femoral neck.[9][11][12]
• Biochemical markers: rapid increases in bone formation markers with relatively modest increases in resorption markers, consistent with a strong anabolic window.[11]

The ACTIVE‑Extension (ACTIVExtend) study followed women who had received abaloparatide or placebo with 2 years of subsequent alendronate therapy.[9][11][12] Participants previously treated with abaloparatide maintained or further improved BMD and had sustained reductions in vertebral and nonvertebral fracture risk compared with those initially on placebo.[9][11][12]

Additional clinical data

Narrative and structured reviews summarize multiple phase 2 and phase 3 studies in postmenopausal osteoporosis and in men with osteoporosis:[9][11][12][14]

• Phase 2 dose‑finding trials in postmenopausal women showed dose‑dependent increases in lumbar spine BMD over 6–18 months with intermittent abaloparatide, supporting the 80 µg daily dose.[9][14]
• A phase 3 study in men with osteoporosis (approximately 225–250 participants) demonstrated significant lumbar spine BMD increases versus placebo at 12 months, with safety findings qualitatively similar to those in women; detailed fracture endpoints were limited due to sample size.[9]

No large completed phase 3 fracture outcome trials have been published for men, and fracture data in this population remain limited.[9]

Preclinical and translational studies

Preclinical studies provide mechanistic and translational support:

• In rodent models, abaloparatide produces greater increases in bone mass and strength than teriparatide at similar or lower doses, with less cortical porosity and smaller increases in bone resorption markers.[11][13]
• In vitro analyses show abaloparatide has a lower EC50 for cAMP formation (2.3‑fold) and β‑arrestin recruitment (1.6‑fold) than teriparatide at PTH1R, reflecting potent receptor activation with distinct signaling kinetics.[13]
• In osteoarthritis models, abaloparatide stimulates chondrogenesis while reducing intracellular reactive oxygen species in mesenchymal stem cell cultures, suggesting potential utility in cartilage regeneration.[2]
• Local or scaffold‑based delivery of abaloparatide via injectable hydrogels enhances bone regeneration in rat bone defect models.[7]
• Local submucosal administration combined with mechanical force promotes alveolar bone augmentation via focal adhesion kinase (FAK)–mediated periosteal osteogenesis in craniofacial models.[4]

Clinical and research uses

Approved indications

• United States: Abaloparatide (Tymlos) is approved for treatment of postmenopausal women with osteoporosis at high risk for fracture, including those with a history of osteoporotic fracture, multiple risk factors, or who have failed or are intolerant to other available osteoporosis therapy.[9][11][12] More recent labeling also includes treatment of men with osteoporosis at high fracture risk, based on BMD data; fracture risk reduction data in men are more limited.[9]

Off‑label and investigational contexts

• Osteoporosis in other high‑risk groups: Potential interest exists in use for glucocorticoid‑induced osteoporosis or severe osteoporosis in younger individuals, but robust controlled data are lacking; such use would be off‑label.[9][11]
• Bone regeneration and orthopedic indications: Preclinical work explores abaloparatide for enhancing bone healing in long‑bone defects and spinal or craniofacial applications, often using local delivery systems (e.g., hydrogels, periosteal injections).[4][7]
• Cartilage and osteoarthritis: In vitro and early in vivo work suggests abaloparatide stimulates chondrogenesis and may mitigate oxidative stress in cartilage progenitors, but there are no established clinical indications.[2]

No major regulatory authority has yet approved abaloparatide for indications beyond osteoporosis.

Dosing context

Clinical dosing information here is descriptive from published trials and product information and is not a prescribing recommendation.

• In pivotal osteoporosis trials and the US product label, abaloparatide is administered as a once‑daily subcutaneous injection of 80 µg into the periumbilical region of the abdomen.[9][11][12][14]
• Treatment duration in trials was typically up to 18 months, followed by transition to an antiresorptive agent such as alendronate to maintain BMD gains.[9][11][12]
• Total lifetime duration of use is limited (e.g., not exceeding a cumulative 2 years for PTH/PTHrP analogs) due to rodent osteosarcoma findings, in line with class labeling; exact wording and limits depend on regulator and updated label.[9][11]

Pharmacokinetics: abaloparatide has rapid absorption and elimination after subcutaneous administration, with a short plasma half‑life on the order of 1 hour in humans, supporting once‑daily dosing.[9][11] Dose adjustments, if any, in renal impairment or other subgroups are guided by label and clinical judgment; detailed protocols vary and are not fully standardized in the literature.[9]

Safety profile

Common adverse effects

Across phase 2 and 3 studies in postmenopausal women and men, the most frequently reported adverse events include:[9][11][12][14]

• Injection‑site reactions (erythema, pain, swelling)
• Dizziness, palpitations, and orthostatic hypotension, typically transient and occurring soon after injection
• Nausea, headache, fatigue
• Hypercalciuria and modest increases in serum calcium; clinically significant hypercalcemia was relatively infrequent and generally less common than with teriparatide.[9][11]

Small, transient increases in heart rate and mild decreases in blood pressure have been observed shortly after dosing.[9] Laboratory changes include increases in bone turnover markers consistent with osteoanabolic activity.[11]

Serious and long‑term safety concerns

• Osteosarcoma (class warning): In rat carcinogenicity studies, lifetime daily exposure to abaloparatide led to increased incidence of osteosarcoma and other bone tumors, similar to findings with teriparatide.[9][11][14] Although no clear signal of osteosarcoma has been observed in humans to date, a boxed warning and lifetime duration limits are included in labeling.[9]
• Hypercalcemia and hypercalciuria: Clinically significant hypercalcemia or hypercalciuria can occur, particularly in individuals with pre‑existing hypercalcemia or impaired renal calcium excretion; careful monitoring is recommended in practice.[9][11]

Contraindications and cautions

Labeling and expert reviews recommend avoiding abaloparatide in patients with conditions predisposing to osteosarcoma or excess bone turnover, including:[9][11][14]

• Bone malignancies or bone metastases
• Paget disease of bone
• Unexplained elevations of alkaline phosphatase of skeletal origin
• Prior external‑beam or implant radiotherapy involving the skeleton
• Pediatric or young adult patients with open epiphyses

Additional cautions:

• Pre‑existing hypercalcemia or severe renal impairment may increase risk of adverse calcium‑related effects.[9][11]
• Concomitant medications affecting calcium homeostasis may require monitoring and adjustment.

Postmarketing data are still evolving; long‑term fracture and safety surveillance continues.[9][11]

Regulatory status

• United States (FDA): Abaloparatide (Tymlos) is approved as a subcutaneous injection for treatment of osteoporosis in postmenopausal women at high risk for fracture, and more recently for men with osteoporosis at high fracture risk.[9][11][12] Labeling includes a boxed warning regarding osteosarcoma risk based on rodent data and limits lifetime duration of use of PTH/PTHrP analogs.[9]

• European Union (EMA): A marketing authorization for abaloparatide under the trade name Eladynos was once granted by the European Commission for treatment of osteoporosis in postmenopausal women at increased fracture risk, but this authorization was subsequently withdrawn at the request of the marketing authorization holder before commercial launch.[9] As a result, abaloparatide is not widely marketed in the EU.

• Other regions: Regulatory status varies; some countries have not approved abaloparatide or have limited availability. Up‑to‑date local regulatory documents should be consulted for regional status.

Abaloparatide remains primarily an osteoanabolic option in jurisdictions where approved, typically reserved for patients at very high fracture risk or those who have failed or are intolerant of antiresorptive therapies.[11][12]